ELSEVIER

Atherosclerosis 126 (1996) 347–350

atherosclerosis

Author index

Volume 126 (1996)

Alam, R., S. Kataoka, S. Alam, F. Yatsu, Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: role of protein kinase C **126**, 207
Alam, S., see Alam, R. **126**, 207
Alavi, M.Z., see Wang, H. **126**, 95
Albanese, M., see Feussner, G. **126**, 177
Alessandri, C., see Iuliano, L. **126**, 131
Allegra, L., see Blasi, F. **126**, 341
Arveiler, D., see Herrmann, S.-M. **126**, 299
Arveiler, D., see Malinow, M.R. **126**, 27
Aston, C.E., see Sanghera, D.K. **126**, 35
Azzi, A., see Şirikçi, Ö. **126**, 253

Bach, R.G., see Miller, D.D. **126**, 1
Bailey, S.R., see Miller, D.D. **126**, 1
Bard, J.-M., see Herrmann, S.-M. **126**, 299
Barnes, J.F., see Farish, E. **126**, 77
Blanc, H., see Herrmann, S.-M. **126**, 299
Blann, A., J. Morris, C. McCollum, Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin **126**, 227
Blasi, F., M.L. Ranzi, M. Erba, P. Tarsia, R. Raccanelli, L. Fagetti, L. Allegra, No evidence for the presence of *Helicobacter pylori* in atherosclerotic plaques in abdominal aortic aneurysm specimens **126**, 341
Blazek, I., see Leitinger, N. **126**, 305
Bredie, S.J.H., J.M. Vogelaar, P.N.M. Demacker, A.F.H. Stalenhoef, Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia **126**, 313
Brown, A., see Farish, E. **126**, 77
Brun, L.-D., see Torres, A.L. **126**, 163
Bryan, N., see Zuckerman, S.H. **126**, 65

Calder, A., see Farish, E. **126**, 77
Camastra, C., see Iuliano, L. **126**, 131
Cambien, F., see Herrmann, S.-M. **126**, 299
Cambien, F., see Malinow, M.R. **126**, 27
Cameron, J., see Sherrard, B. **126**, 277
Camps, J., see Joven, J. **126**, 243
Carrilho, A.J.F., see Lottenberg, A.M.P. **126**, 265
Chen, Q., see Stulnig, T.M. **126**, 85
Colavita, A.R., see Iuliano, L. **126**, 131

Dart, A., see Sherrard, B. **126**, 277
de Almeida, E., see Jorge, P.A.R. **126**, 43
Demacker, P.N.M., see Bredie, S.J.H. **126**, 313
Derr, J., see Mustad, V. **126**, 117
Després, J.-P., see Torres, A.L. **126**, 163
Dubick, M.A., see Killion, S.L. **126**, 289
Ducimetiere, P., see Malinow, M.R. **126**, 27
Dzien, A., see Hoppichler, F. **126**, 333

Endler, G., see Leitinger, N. **126**, 305
Erba, M., see Blasi, F. **126**, 341
Eskelson, C.D., see Killion, S.L. **126**, 289
Espinel, E., see Joven, J. **126**, 243
Evans, A.E., see Malinow, M.R. **126**, 27
Evans, A., see Herrmann, S.-M. **126**, 299

Fagetti, L., see Blasi, F. **126**, 341
Farish, E., K. Spowart, J.F. Barnes, C.D. Fletcher, A. Calder, A. Brown, D.M. Hart, Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions **126**, 77
Farrar, M., see Miller, D.D. **126**, 1
Feres, M.C., see Maranhão, R.C. **126**, 15
Ferrell, R.E., see Sanghera, D.K. **126**, 35
Feussner, G., M. Albanese, A. Valencia, Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg_{136} → Cys) variant **126**, 177
Fiorani, P., see Iuliano, L. **126**, 131
Fletcher, C.D., see Farish, E. **126**, 77
Folsom, A.R., see Iso, H. **126**, 233
Frants, R.R., see Sijbrands, E.J.G. **126**, 197

Gagné, C., see Torres, A.L. **126**, 163
Gevers Leuven, J.A., see Sijbrands, E.J.G. **126**, 197
Gianinni, S.D., see Maranhão, R.C. **126**, 15
Gotto, Jr, A.M., see Yang, C.-Y. **126**, 105
Gu, Z.-W., see Yang, C.-Y. **126**, 105
Gylling, H., T.A. Miettinen, Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease **126**, 325

Hall, K.A., see Killion, S.L. **126**, 289
Harada, S., see Iso, H. **126**, 233
Hart, D.M., see Farish, E. **126**, 77
Havekes, L.M., see Sijbrands, E.J.G. **126**, 197
Herrmann, S.-M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J.-M. Bard, F. Cambien, The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study **126**, 299
Hintze, T.H., see Stephan, Z.F. **126**, 53
Hoffer, M.J.V., see Sijbrands, E.J.G. **126**, 197
Hoppichler, F., M. Lechleitner, C. Traweger, G. Schett, A. Dzien, W. Sturm, Q. Xu, Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction **126**, 333
Hornstra, G., see van de Vijver, L.P.L. **126**, 155
Hu, C.-W., see Stephan, Z.F. **126**, 53
Hunter, G.C., see Killion, S.L. **126**, 289

Iida, M., see Iso, H. **126**, 233
Iso, H., S. Harada, T. Shimamoto, A.R. Folsom, K. Koike, S. Sato, M. Iida, Y. Komachi, Polymorphism of the apolipoprotein B gene and blood lipid concentrations in Japanese and Caucasian population samples **126**, 233
Iuliano, L., A. Signore, S. Vallabajosula, A.R. Colavita, C. Camastra, G. Ronga, C. Alessandri, E. Sbarigia, P. Fiorani, F. Violi, Preparation and biodistribution of ^{99m}technetium labelled oxidized LDL in man **126**, 131

Jarosch, E., see Stulnig, T.M. **126**, 85
Jennings, G., see Sherrard, B. **126**, 277
Jingami, H., see Matsuoka, N. **126**, 221
Jorge, P.A.R., M.R. Osaki, E. de Almeida, L.C. Neto, K. Metze, Effects of vitamin E on endothelium-dependent coronary flow in hypercholesterolemic dogs **126**, 43
Joven, J., E. Espinel, J.M. Simó, E. Vilella, J. Camps, A. Oliver, The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia **126**, 243
Jürgens, G., see Stulnig, T.M. **126**, 85

Kamboh, M.I., see Sanghera, D.K. **126**, 35
Kataoka, S., see Alam, R. **126**, 207
Killion, S.L., G.C. Hunter, C.D. Eskelson, M.A. Dubick, C.W. Putnam, K.A. Hall, C.A. Luedke, R.L. Misiorowski, J.D. Schilling, K.E. McIntyre, Vitamin E levels in human atherosclerotic plaque: the influence of risk factors **126**, 289
Kimm, S.Y.S., see Sanghera, D.K. **126**, 35
Kobayashi, K., see Taniguchi, S. **126**, 143
Koike, K., see Iso, H. **126**, 233
Komachi, Y., see Iso, H. **126**, 233
Kris-Etherton, P.M., see Mustad, V. **126**, 117
Kruyssen, D.A.C.M., see van de Vijver, L.P.L. **126**, 155

Lamarche, B., see Torres, A.L. **126**, 163
Lechleitner, M., see Hoppichler, F. **126**, 333
Leitinger, N., C. Pirich, I. Blazek, G. Endler, H. Sinzinger, Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment **126**, 305
Leonards, K.S., see Stephan, Z.F. **126**, 53
Lottenberg, A.M.P., V.S. Nunes, S.A. Lottenberg, A.F.M. Shimabukuro, A.J.F. Carrilho, S. Malagutti, E.R. Nakandakare, R. McPherson, E.C.R. Quintão, Plasma cholesteryl ester synthesis, cholesteryl ester transfer protein concentration and activity in hypercholesterolemic women: effects of the degree of saturation of dietary fatty acids in the fasting and postprandial states **126**, 265
Lottenberg, S.A., see Lottenberg, A.M.P. **126**, 265
Luc, G., see Herrmann, S.-M. **126**, 299
Luc, G., see Malinow, M.R. **126**, 27
Luedke, C.A., see Killion, S.L. **126**, 289
Lupien, P.-J., see Torres, A.L. **126**, 163

Malagutti, S., see Lottenberg, A.M.P. **126**, 265
Malinow, M.R., P. Ducimetiere, G. Luc, A.E. Evans, D. Arveiler, F. Cambien, B.M. Upson, Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease **126**, 27
Maranhão, R.C., M.C. Feres, M.T. Martins, C.H. Mesquita, O. Toffoletto, C.G.C. Vinagre, S.D. Gianinni, F. Pileggi, Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. **126**, 15
Marques-Vidal, P., see Herrmann, S.-M. **126**, 299
Martins, M.T., see Maranhão, R.C. **126**, 15
Masuzaki, H., see Matsuoka, N. **126**, 221
Matsuoka, N., H. Jingami, H. Masuzaki, M. Mizuno, S. Nakaishi, J. Suga, T. Tanaka, T. Yamamoto, K. Nakao, Effects of gemfibrozil administration on very low density lipoprotein receptor mRNA levels in rabbits **126**, 221
McAllister, A.E., see Sanghera, D.K. **126**, 35
McCollum, C., see Blann, A. **126**, 227
McIntyre, K.E., see Killion, S.L. **126**, 289
McPherson, R., see Lottenberg, A.M.P. **126**, 265
Meinders, A.E., see Sijbrands, E.J.G. **126**, 197
Mesquita, C.H., see Maranhão, R.C. **126**, 15
Metze, K., see Jorge, P.A.R. **126**, 43
Miettinen, T.A., see Gylling, H. **126**, 325
Miller, D.D., R.G. Bach, F.O. Tio, S.R. Bailey, C.A. Waters, T.G. Woodworth, J.C. Nichols, S.B. Paige, M. Farrar, Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis **126**, 1
Misiorowski, R.L., see Killion, S.L. **126**, 289
Mizuno, M., see Matsuoka, N. **126**, 221

Moll, D., see Stulnig, T.M. **126**, 85
Moore, S., see Wang, H. **126**, 95
Moorjani, S., see Torres, A.L. **126**, 163
Morris, J., see Blann, A. **126**, 227
Mourão, P.A.S., see Tovar, A.M.F. **126**, 185
Mustad, V., J. Derr, C.C. Reddy, T.A. Pearson, P.M. Kris-Etherton, Seasonal variation in parameters related to coronary heart disease risk in young men **126**, 117

Nakaishi, S., see Matsuoka, N. **126**, 221
Nakandakare, E.R., see Lottenberg, A.M.P. **126**, 265
Nakao, K., see Matsuoka, N. **126**, 221
Nawata, H., see Taniguchi, S. **126**, 143
Neto, L.C., see Jorge, P.A.R. **126**, 43
Nichols, J.C., see Miller, D.D. **126**, 1
Nunes, V.S., see Lottenberg, A.M.P. **126**, 265

Oliver, A., see Joven, J. **126**, 243
Osaki, M.R., see Jorge, P.A.R. **126**, 43
Özer, N.K., see Şi̇ri̇kçi̇, Ö. **126**, 253

Paige, S.B., see Miller, D.D. **126**, 1
Pearson, T.A., see Mustad, V. **126**, 117
Pileggi, F., see Maranhão, R.C. **126**, 15
Pirich, C., see Leitinger, N. **126**, 305
Poirier, O., see Herrmann, S.-M. **126**, 299
Putnam, C.W., see Killion, S.L. **126**, 289

Quintão, E.C.R., see Lottenberg, A.M.P. **126**, 265
Quion, J.A.V., see Yang, C.-Y. **126**, 105

Raccanelli, R., see Blasi, F. **126**, 341
Ranzi, M.L., see Blasi, F. **126**, 341
Reddy, C.C., see Mustad, V. **126**, 117
Ronga, G., see Iuliano, L. **126**, 131

Sanghera, D.K., R.E. Ferrell, C.E. Aston, A.E. McAllister, M.I. Kamboh, S.Y.S. Kimm, Quantitative effects of the apolipoprotein E polymorphism in a biracial sample of 9–10-year-old girls **126**, 35
Sato, S., see Iso, H. **126**, 233
Sbarigia, E., see Iuliano, L. **126**, 131
Schett, G., see Hoppichler, F. **126**, 333
Schilling, J.D., see Killion, S.L. **126**, 289
Schönitzer, D., see Stulnig, T.M. **126**, 85
Sharif, R., see Stephan, Z.F. **126**, 53
Sherrard, B., H. Simpson, J. Cameron, S. Wahi, G. Jennings, A. Dart, LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers **126**, 277
Shimabukuro, A.F.M., see Lottenberg, A.M.P. **126**, 265
Shimamoto, T., see Iso, H. **126**, 233
Signore, A., see Iuliano, L. **126**, 131
Sijbrands, E.J.G., R.G.J. Westendorp, M.J.V. Hoffer, R.R. Frants, A.E. Meinders, J.H.M. Souverijn, J.A. Gevers Leuven, A. Van der Laarse, L.M. Havekes, A.H.M. Smelt, Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients **126**, 197
Simó, J.M., see Joven, J. **126**, 243
Simpson, H., see Sherrard, B. **126**, 277
Sinzinger, H., see Leitinger, N. **126**, 305
Şi̇ri̇kçi̇, Ö., N.K. Özer, A. Azzi, Dietary cholesterol-induced changes of protein kinase C and the effect of vitamin E in rabbit aortic smooth muscle cells **126**, 253
Smelt, A.H.M., see Sijbrands, E.J.G. **126**, 197
Souverijn, J.H.M., see Sijbrands, E.J.G. **126**, 197
Spowart, K., see Farish, E. **126**, 77
Stalenhoef, A.F.H., see Bredie, S.J.H. **126**, 313
Steele, R.E., see Stephan, Z.F. **126**, 53
Stephan, Z.F., E.C. Yurachek, R. Sharif, J.M. Wasvary, K.S. Leonards, C.-W. Hu, T.H. Hintze, R.E. Steele, Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects **126**, 53
Stulnig, T.M., G. Jürgens, Q. Chen, D. Moll, D. Schönitzer, E. Jarosch, G. Wick, Properties of low density lipoproteins relevant to oxidative modifications change paradoxically during aging **126**, 85
Sturm, W., see Hoppichler, F. **126**, 333
Suga, J., see Matsuoka, N. **126**, 221

Takayanagi, R., see Taniguchi, S. **126**, 143
Tanaka, T., see Matsuoka, N. **126**, 221
Taniguchi, S., T. Yanase, K. Kobayashi, R. Takayanagi, H. Nawata, Dehydroepiandrosterone markedly inhibits the accumulation of cholesteryl ester in mouse macrophage J774-1 cells **126**, 143
Tarsia, P., see Blasi, F. **126**, 341
Tio, F.O., see Miller, D.D. **126**, 1
Toffoletto, O., see Maranhão, R.C. **126**, 15
Torres, A.L., S. Moorjani, M.-C. Vohl, C. Gagné, B. Lamarche, L.-D. Brun, P.-J. Lupien, J.-P. Després, Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. **126**, 163
Tovar, A.M.F., P.A.S. Mourão, High affinity of a fucosylated chondroitin sulfate for plasma low density lipoprotein **126**, 185
Traweger, C., see Hoppichler, F. **126**, 333

Upson, B.M., see Malinow, M.R. **126**, 27

Valencia, A., see Feussner, G. **126**, 177
Valentinova, N.V., see Yang, C.-Y. **126**, 105
Vallabajosula, S., see Iuliano, L. **126**, 131
Van der Laarse, A., see Sijbrands, E.J.G. **126**, 197
van de Vijver, L.P.L., G. van Poppel, A. van Houwelingen, D.A.C.M. Kruyssen, G. Hornstra, *Trans* unsaturated fatty acids in plasma phospholipids and coronary heart disease: a case-control study **126**, 155
van Houwelingen, A., see van de Vijver, L.P.L. **126**, 155

van Poppel, G., see van de Vijver, L.P.L. **126**, 155
Vilella, E., see Joven, J. **126**, 243
Vinagre, C.G.C., see Maranhão, R.C. **126**, 15
Violi, F., see Iuliano, L. **126**, 131
Vogelaar, J.M., see Bredie, S.J.H. **126**, 313
Vohl, M.-C., see Torres, A.L. **126**, 163

Wahi, S., see Sherrard, B. **126**, 277
Wang, H., S. Moore, M.Z. Alavi, Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization **126**, 95
Wasvary, J.M., see Stephan, Z.F. **126**, 53
Waters, C.A., see Miller, D.D. **126**, 1
Westendorp, R.G.J., see Sijbrands, E.J.G. **126**, 197
Wick, G., see Stulnig, T.M. **126**, 85
Woodworth, T.G., see Miller, D.D. **126**, 1

Xie, Y.-H., see Yang, C.-Y. **126**, 105
Xu, Q., see Hoppichler, F. **126**, 333

Yamamoto, T., see Matsuoka, N. **126**, 221
Yanase, T., see Taniguchi, S. **126**, 143
Yang, C.-Y., Z.-W. Gu, Y.-H. Xie, N.V. Valentinova, M. Yang, D. Yeshurun, J.A.V. Quion, A.M. Gotto, Jr, Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia **126**, 105
Yang, M., see Yang, C.-Y. **126**, 105
Yatsu, F., see Alam, R. **126**, 207
Yeshurun, D., see Yang, C.-Y. **126**, 105
Yurachek, E.C., see Stephan, Z.F. **126**, 53

Zuckerman, S.H., N. Bryan, Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL) **126**, 65

ELSEVIER

Atherosclerosis 126 (1996) 351–352

atherosclerosis

Subject index

Volume 126 (1996)

Abdominal aortic aneurysm **126**, 341
Acetylcholine **126**, 43
African American disease risk **126**, 35
Aging **126**, 85
Angioplasty **126**, 1
Antibodies **126**, 333
Anti-oxidants **126**, 85
Apo B gene **126**, 233
ApoE **126**, 197
Apo E2 (Arg_{136} → Cys) **126**, 177
Apolipoprotein A-1 **126**, 117
Apolipoprotein B100 **126**, 117
Apolipoprotein E **126**, 35, 105, 177
Apolipoprotein E polymorphism **126**, 313
Atherosclerosis **126**, 1, 53, 85, 95, 131, 207, 227, 253, 299, 305, 333
Atherosclerotic risk factors **126**, 289

Blood total cholesterol **126**, 233

Calcium antagonist **126**, 207
Children **126**, 163
Cholesterol **126**, 15, 53
Cholesterol absorption and synthesis **126**, 325
Cholesterol esterification **126**, 143
Cholesterol ester reduction **126**, 143
Cholesteryl ester cycle **126**, 143
Cholesteryl ester storage **126**, 143
Cholesteryl ester transfer protein **126**, 265
Chondroitin 6-sulfate **126**, 185
Chylomicrons **126**, 15
Clentiazem **126**, 207
Combined hyperlipidemia **126**, 197
Coronary artery disease **126**, 15, 325
Coronary atherosclerosis **126**, 155
Coronary heart disease **126**, 27, 277, 333, 341
Coronary risk factors **126**, 233
Cross-cultural comparison **126**, 233
Cytokines **126**, 1
Cytotoxic therapy **126**, 1

Dehydroepiandrosterone (DHEA) **126**, 143
Dextrane-sulfate LDL-apheresis **126**, 305
DHEA analogue **126**, 143
Dog **126**, 43
Dominant mode of inheritance **126**, 177
Dysbetalipoproteinemia **126**, 177

Emulsions **126**, 15
Endothelium-dependent coronary flow **126**, 43
Extracellular matrix **126**, 95

Familial combined hyperlipidemia **126**, 313
Familial hypercholesterolemia **126**, 163
Free radicals **126**, 131
Fucans **126**, 185
Fucosylated chondroitin sulfate **126**, 185
Fusion toxin **126**, 1

Gemfibrozil **126**, 105, 221
Gene expression **126**, 95
Genetic epidemiology **126**, 163
Genetic polymorphism **126**, 35
Genetics **126**, 313
Glucose **126**, 277
Glycosaminoglycans **126**, 185

Heat shock proteins **126**, 333
Helicobacter pylori **126**, 341
Heparin **126**, 185
Hormone replacement **126**, 77
Hypercholesterolemia **126**, 43, 265
Hyperinsulinemia **126**, 197
Hyperlipidemia **126**, 105, 243
Hypertension **126**, 207
Hypoalbuminemia **126**, 243
Hypolipidemic **126**, 53

Imaging **126**, 131
Injury **126**, 95
In situ hybridization **126**, 95

Insulin **126**, 277
Interleukin-2 **126**, 1
Isoprostanes **126**, 305

6-keto-$PGF_{1\alpha}$ **126**, 117

LDL **126**, 53, 185
LDL and HDL kinetics **126**, 325
LDL-biodistribution **126**, 131
LDL-cholesterol **126**, 35
LDL-oxidation **126**, 305
LDL-receptor gene **126**, 163
LDL size **126**, 105
LDL subfractions **126**, 77
Lecithin-cholesterol-acyl transferase **126**, 265
Lipid peroxidation **126**, 85
Lipid peroxides **126**, 289
Lipoperoxides **126**, 65
Lipoprotein(a) **126**, 77
Lipoproteins **126**, 15, 77, 131, 185, 243
Low density lipoprotein particle size **126**, 277
Low density lipoproteins **126**, 65
Low-density lipoproteins (LDL) **126**, 85
L-T_3 **126**, 53
lysosomal cholesterol transport **126**, 143

Macrophages **126**, 65
Membranous nephropathy **126**, 243
Myocardial infarction **126**, 27, 299, 333

Nephrotic syndrome **126**, 243

Oncotic pressure **126**, 243
Oxidation **126**, 65
Oxidized-LDL **126**, 131

Paraoxonase **126**, 299
Particle size **126**, 197
Phagocytosis **126**, 65
Phenotypic expression **126**, 313
Phospholipids **126**, 155
Plant sterols **126**, 325
Plasma homocyst(e)ine **126**, 27
Plasma lipoproteins **126**, 35, 105
Polymorphism **126**, 233, 299
Polyunsaturated fatty acids **126**, 85, 265
Postmenopausal **126**, 77
Proliferation **126**, 207
Protein kinase C **126**, 207, 253
Proteinuria **126**, 243

Rabbit **126**, 221
Risk factors **126**, 27
RT-PCR **126**, 95

Saturated fatty acids **126**, 265
Seasonal variation **126**, 117
SENIEUR protocol **126**, 85
Smooth muscle cells **126**, 207, 253
Sodium nitroprusside **126**, 43
Soluble E-selectin **126**, 227
Soluble L-selectin **126**, 227
Soluble P-selectin **126**, 227
Sulfated polysaccharides **126**, 185

Thiobarbituric acid reactive substances **126**, 305
Thyromimetic **126**, 53
TIMP **126**, 95
Trans fatty acid **126**, 155
Triglyceride **126**, 277
Triglycerides **126**, 15
TXB_2 **126**, 117
Type II diabetes mellitus **126**, 325
Type III hyperlipoproteinemia **126**, 177

Vitamin E **126**, 43, 253, 289
VLDL **126**, 197
VLDL composition **126**, 105
VLDL receptor **126**, 221
VLDL subfractions **126**, 105